Methyl 5-(Trifluoromethyl)-1,3-Thiazole-4-Carboxylate

Controlled hydrolysis of the methyl ester to the corresponding carboxylic acid is a prerequisite for most downstream amidations and represents the first scale-up gate in pharmaceutical intermediate manufacturing. The electron-withdrawing influence of the 5‑trifluoromethyl group on the thiazole ring substantially increases the electrophilicity of the ester carbonyl, rendering saponification rapid even with dilute sodium hydroxide, yet the same activation renders the heterocycle vulnerable to nucleophilic ring-opening if local alkalinity exceeds pH 12.5. In a 50 L jacketed glass-lined reactor equipped with a retreat-curve impeller and a pH probe inserted through a PTFE dip tube, 1.05 equivalents of 1.0 M NaOH are metered below the liquid surface at a rate that maintains internal temperature below 25 °C and bulk pH between 10.8 and 11.3. Process analytical technology, typically a ReactIR 15 probe monitoring the disappearance of the carbonyl stretch at 1728 cm⁻¹, triggers termination when residual ester falls below 0.5 area%. Neutralisation with 2.0 M hydrochloric acid precipitates 5‑(trifluoromethyl)‑1,3‑thiazole‑4‑carboxylic acid, which is isolated by centrifugation, washed with chilled de‑ionised water until the conductivity of the filtrate drops below 50 µS/cm, and dried under vacuum at 40 °C to a loss‑on‑drying below 0.3%. The free acid is then converted to the acyl chloride using thionyl chloride (1.3 eq) and catalytic dimethylformamide (0.05 eq) in toluene at 55–60 °C; off‑gas scrubbing through a 10% NaOH packed column is mandatory to capture SO₂ and HCl. Without in‑line FT‑IR monitoring, over‑chlorination can form a mixed anhydride impurity that co‑crystallises with the desired amide product. Coupling with a heterocyclic amine—selected from a kinase‑inhibitor scaffold library—proceeds in tetrahydrofuran at –5 to 0 °C using N,N‑diisopropylethylamine (2.2 eq) as an acid scavenger. The resulting methyl 5‑(trifluoromethyl)‑1,3‑thiazole‑4‑carboxamide requires recrystallisation from n‑heptane:ethyl acetate (85:15 v/v) with a controlled cooling ramp of 0.5 °C/min to achieve a polymorphically pure Form I, confirmed by powder X‑ray diffraction against a reference standard whose characteristic peaks appear at 2θ 9.8°, 14.2°, and 21.7°. A batch release for a GMP‑grade intermediate bound for a Phase II clinical candidate enforces HPLC purity ≥ 99.9 area% (C18 stationary phase, 25 mM phosphate buffer pH 3.0/acetonitrile gradient), any single unspecified impurity ≤ 0.05%, residual thionyl chloride and DMF below limits of 10 ppm and 50 ppm respectively as per ICH Q3C, and endotoxin content ≤ 0.5 EU/mg by LAL assay. Material failing the chiral purity criterion is rejected; although the core thiazole is achiral, atropisomerism introduced by the amide appendage has been documented during high‑throughput screening of matched molecular pairs targeting the ATP‑binding pocket of a specific kinase.

Hydrazinolysis of the methyl ester proceeds smoothly with hydrazine monohydrate (5.0 eq) in ethanol at reflux for 4 h, yielding the acyl hydrazide as a hygroscopic solid that must be stored over phosphorous pentoxide. After flash chromatography on silica gel (ethyl acetate/methanol, 9:1), the hydrazide reacts with aldehydes generated by periodate oxidation of carbohydrate moieties on monoclonal antibodies. Conjugation is conducted in 100 mM sodium acetate buffer, pH 5.5, at a protein concentration of 5 mg/mL, using 1.0 mM sodium cyanoborohydride as a mild reductant to stabilise the hydrazone adduct. Residual unconjugated small molecule is removed by size‑exclusion chromatography on a Sephadex G‑25 column equilibrated with phosphate‑buffered saline. The bioconjugate retains target binding affinity within 1.5‑fold of the native antibody when the fluorophore‑to‑antibody ratio is kept between 2.8 and 4.2, as measured by UV‑Vis spectrometry. For research‑grade reagents, a sterility filter (0.22 µm PVDF) is employed and the final preparation is aliquoted into amber vials under nitrogen to prevent oxidative degradation of the thiazole ring. Any batch showing accelerated aggregation above 5% monomer loss by dynamic light scattering after 48 h at 37 °C is discarded; the tetrafluoroborate counter‑ion introduced during cyanoborohydride addition must be quantified by ion chromatography and kept below 50 ppm to avoid downstream interference in cell‑based assays.

When Agrochemical Teams Target the 4‑Carboxamide Framework to Combat Basidiomycete Pathogens

In high‑volume agrochemical synthesis, methyl 5‑(trifluoromethyl)‑1,3‑thiazole‑4‑carboxylate is most frequently advanced to the corresponding arylamide, which serves as the pharmacophore core of systemic succinate dehydrogenase inhibitor (SDHI) fungicides aimed at sheath blight (Rhizoctonia solani). A streamlined two‑step, one‑pot process has been qualified at the 500 L scale: acid formation by alkaline hydrolysis, solvent switch to toluene via azeotropic distillation to a water content below 500 ppm, and in‑situ activation with thionyl chloride at 60 °C. The acid chloride solution is then fed into a pre‑cooled slurry of 2′,6′‑dibromo‑4‑trifluoromethoxyaniline (1.02 eq) and triethylamine (1.2 eq) in toluene at 0–5 °C over 90 min. Excessive exotherm during the coupling phase above 10 °C generates a dimeric urea by‑product that is difficult to purge and measurable by LC‑MS at m/z 817.0; the batch is typically reprocessed through a charcoal‑celite pad if this impurity exceeds 0.15 area%. Crystallisation from methanol/water (70:30) with seeding affords the technical active ingredient, 2′,6′‑dibromo‑4‑trifluoromethoxy‑5‑(trifluoromethyl)‑1,3‑thiazole‑4‑carboxamide, in an overall yield of 78–82% and a purity of ≥ 98.5% by GLC‑FID (capillary column DB‑5, temperature programme 150 °C to 280 °C at 10 °C/min). Particle size distribution is controlled to D₅₀ ≤ 5 µm via jet milling for subsequent suspension concentrate formulation; bi‑modal distributions create Ostwald ripening in the final SC product and are rejected per CIPAC MT 187. Process waste streams contain fluorinated aromatic amines and are routed through an activated carbon fixed‑bed adsorber with a bed depth of 2.0 m and empty‑bed contact time of 30 min; effluent is monitored for total organofluorine content using combustion ion chromatography to stay below the 2.0 mg/L discharge limit mandated by local REACH implementation. A validated analytical suite quantifies the active ingredient content to 97.0–103.0% and the maximum content of the des‑bromo debrominated analogue and the 4‑trifluoromethoxy hydrolysis product to ≤ 0.5% each, per FAO specification 798/TC. The final carboxamide is stored away from moisture and amine‑containing stabilisers because the thiazole ring can undergo hydrolytic scission at the C2‑N bond under prolonged exposure to basic microenvironments—a degradation pathway confirmed by accelerated stability chambers at 54 °C and 75% RH over 14 days, which generates a 4‑amino‑2‑trifluoromethylthiazole fragment detectable by headspace GC‑MS.

Direct integration of the intact methyl ester into pharmacomimetic scaffolds without prior hydrolysis is leveraged when the carbomethoxy group plays a structural role in target engagement, for instance in transient receptor potential (TRP) channel modulators. Here the intact ester is coupled under strictly anhydrous Buchwald‑Hartwig conditions to a halogenated pyridopyrimidine core: a mixture of palladium(II) acetate (2 mol%) and Xantphos (3 mol%) in dioxane is pre‑activated at 90 °C for 15 min before adding methyl 5‑(trifluoromethyl)‑1,3‑thiazole‑4‑carboxylate (1.0 eq), the aryl bromide (1.15 eq), and cesium carbonate (2.5 eq). The transformation is held at 100 °C for 20 h under argon with overhead stirring; conversion is followed by UPLC at 210 nm. Reaction work‑up involves filtration through a plug of diatomaceous earth to remove palladium residues, a wash with 5% aqueous sodium bisulfite to complex heavy metals, and concentration in vacuo. The crude is purified by automated flash chromatography on a 330 g silica cartridge using an ethyl acetate/hexane gradient, yielding the cross‑coupled product as an off‑white solid. Any residual palladium above the 10 ppm limit specified by USP <232>/<233> necessitates a secondary treatment with a polymer‑bound trimercaptotriazine scavenger. The finished intermediate is stored under argon at –20 °C because the thiazole 2‑position remains susceptible to autoxidation, forming an N‑oxide impurity that co‑elutes with the desired product on a Kinetex biphenyl column; acceptance criteria mandate a relative retention time window of 0.98–1.04 and peak purity above 995 as measured by photodiode array detector.

Palladium‑Catalyzed Direct Arylation — A Thiazole‑Directed C–H Activation Opportunity

Rather than function as an electrophilic halide surrogate, the 1,3‑thiazole ring bearing a 4‑carbomethoxy and 5‑trifluoromethyl substitution pattern can be exploited as a C–H nucleophile for atom‑economical biaryl construction. Using an electron‑deficient aryl bromide such as methyl 4‑bromobenzoate (1.2 eq), palladium(II) acetate (5 mol%), tricyclohexylphosphine tetrafluoroborate (10 mol%), and potassium acetate (2.0 eq) in anhydrous N,N‑dimethylacetamide at 110 °C under nitrogen, arylation proceeds selectively at the 2‑position of the thiazole over 20–24 h. In‑process control by LC‑MS reveals a critical kinetic bifurcation: if the water content exceeds 300 ppm, a competing protodecarboxylation of the 4‑ester substituent occurs, yielding 5‑(trifluoromethyl)‑1,3‑thiazole as a major side product identified by its characteristic ¹⁹F NMR signal at −61.2 ppm. Reaction calorimetry in a 1 L EasyMax reactor shows an exotherm of −78 kJ/mol upon catalyst activation; a ramp‑controlled heating protocol from 50 °C to 110 °C at 0.5 °C/min prevents thermal accumulation that otherwise leads to a runaway at the 105 °C threshold. Post‑reaction, the palladium black precipitate is removed through a depth filter cartridge, and the resulting solution is partitioned between methyl tert‑butyl ether and 1.0 M hydrochloric acid. The organic layer is distilled under reduced pressure (10 mbar, steam bath 45 °C) and the residue is recrystallised from cyclohexane:toluene (4:1) to obtain the 2‑arylated thiazole ester as colourless needles showing a melting point of 144–146 °C and HPLC purity of >99.0%. This intermediate serves as a strategic precursor to 2,5‑disubstituted thiazoles where the 4‑carbomethoxy group is subsequently transformed—via hydrazide or amide—into a third diversity vector for SAR studies at a contract research organisation. It is noteworthy that attempts to replace DMAc with dimethylformamide led to 5–8% defluorination at the 5‑position, attributed to formate‑mediated hydrodefluorination, a liability confirmed by ¹⁹F NMR disappearance of the −65.3 ppm resonance.

Does the Trifluoromethyl Group Impart Sufficient Thermal Stability for Liquid Crystal Intermediates?

Thermotropic liquid crystalline behaviour has been examined for a series of 4‑alkoxyphenyl esters derived from 5‑(trifluoromethyl)‑1,3‑thiazole‑4‑carboxylic acid, where the methyl ester is transesterified with a para‑substituted phenol bearing a linear alkyl chain. The reaction uses titanium(IV) isopropoxide (0.1 eq) in o‑xylene at reflux with continuous removal of methanol through a Dean‑Stark trap under a gentle nitrogen stream. A stoichiometric excess of the phenol (1.3 eq) drives the equilibrium, and the catalyst is ultimately quenched with 10% aqueous citric acid. The crude phenyl ester displays a crystal‑to‑nematic transition at 112 °C and a nematic‑to‑isotropic clearing point at 221 °C as measured by differential scanning calorimetry at a scan rate of 5 °C/min; the mesophase width of 109 °C is attributed to the strong dipole moment of the terminal trifluoromethyl group combined with the rigid thiazole ring, which suppresses smectic ordering. Polarising optical microscopy confirms a Schlieren texture characteristic of a nematic phase. For use as a single‑compound liquid crystal or a dopant in twisted nematic mixtures, the substance must pass a resistivity test: 1 g is dissolved in 10 mL of ultra‑pure cyclohexanone and measured using a 6514 electrometer with a concentric‑ring electrode, yielding a volume resistivity ≥ 5×10¹² Ω·cm after triple column chromatography (alumina, silica, alumina) to remove ionic residues. Single‑batch rejects are common if the saponification value deviates from the theoretical 162 mg KOH/g by more than ±2%; such deviation signals incomplete transesterification, which would introduce dielectric anisotropy inconsistencies in the final formulation. Published data for this specific ester’s rotational viscosity (γ₁) and elastic constants (k₁₁/k₃₃) are limited; however, extrapolation from homologous 1,3‑thiazole mesogens suggests values in the range of 120–180 mPa·s at 20 °C and a bending‑to‑splay ratio of 1.4–1.7, suitable for high‑speed multiplex driving schemes. All glassware used during purification is pre‑rinsed with 0.1 M HCl and deionised water to eliminate sodium ions that lower the voltage holding ratio below the 99.0% threshold required by automotive display specifications. The final material is packaged under argon in borosilicate ampoules with PTFE‑lined caps and stored at 4 °C to retard ester hydrolysis, which would otherwise generate free acid and raise the ionic content beyond acceptable levels within 6 months.

Fluorous Biphasic Ligand Synthesis and Catalyst Recycling in Continuous‑Flow Hydrogenation

Attachment of a perfluorinated ponytail to the thiazole core affords a fluorous ligand that partitions preferentially into the fluorous phase of a biphasic system, enabling catalyst recovery and recycle in asymmetric hydrogenation. A representative sequence begins with amidation of methyl 5‑(trifluoromethyl)‑1,3‑thiazole‑4‑carboxylate with 1H,1H‑perfluorooctylamine (1.0 eq) using 1‑[bis(dimethylamino)methylene]‑1H‑1,2,3‑triazolo[4,5‑b]pyridinium 3‑oxid hexafluorophosphate (HATU, 1.1 eq) and N‑methylmorpholine (3.0 eq) in dichloromethane at ambient temperature. The amide intermediate is reduced with borane‑tetrahydrofuran complex (3.0 eq) to the corresponding secondary amine, which is subsequently loaded onto a continuous‑flow hydrogenation reactor packed with a Pd/C heterogeneous catalyst. The reactor consists of a 10 mm internal diameter stainless steel column packed with 5% Pd/C (wet catalyst, particle size 50–70 µm) to a bed height of 150 mm. A solution of the fluorous amine (0.05 M in perfluoromethylcyclohexane) and the chiral rhodium precatalyst (1.0 mol%) is co‑fed with hydrogen at 30 bar back‑pressure through a gas‑liquid mixer at a total flow rate of 1.0 mL/min. Turnover numbers exceeding 8,000 have been recorded for the enantioselective reduction of methyl 2‑acetamidoacrylate, with enantiomeric excess maintained at 94–96% over 10 consecutive cycles before a noticeable drop is observed due to leaching of rhodium into the organic product stream, which is quantitated by ICP‑MS at levels of 0.8–1.2 ppm per pass. The perfluoro‑phase containing the thiazole‑based ligand is separated in‑line using a hydrophobic membrane separator and returned to the feed tank; the make‑up of fresh ligand (0.5 mol% per cycle) compensates for mechanical losses. All steps are conducted in a fume hood certified for fluorinated waste; the overall process is compatible with ICH Q11 concepts of continuous processing and has been demonstrated at lab scale with a residence time of 45 min for the hydrogenation stage, achieving a space‑time yield of 0.8 kg·L⁻¹·day⁻¹. The fluorous amide precursor is analysed for the presence of non‑fluorinated homologue by ¹⁹F NMR using 1,4‑difluorobenzene as an internal standard; the fluorous purity must exceed 97 mol% to guarantee clean phase separation, otherwise emulsification occurs at the fluorous‑organic interface and reduces the recovered catalyst activity by 30–40%.